16684-06-3

Basic information

• Product Name: 7-epi-Clindamycin
• Synonyms: 7-epi-Clindamycin;Epiclindamycin;Methyl 7-chloro-6,7,8-trideoxy-6-[[[(2S)-1-methyl-4β-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-D-erythro-α-D-galacto-octopyranoside;ClindaMycin iMpurity C (7-Epi ClindaMycin) hydrochloride;[14C]-Clindamycin;Clindamycin C;Methyl 7-Chloro-6,7,8-trideoxy-6-[[[(2S,4R)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-D-erythro-α-D-galacto-octopyranoside;Clindamycin HCl EP Impurity C
• CAS NO: 16684-06-3
• Molecular Formula: C₁₈H₃₃ClN₂O₅S
• Molecular Weight: 424.98302
• EINECS: 241-424-8
• Product Categories: Carbohydrates & Derivatives;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 16684-06-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 628.1±55.0 °C(Predicted)
• Appearance: /
• Density: 1.29±0.1 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly), Water (Slightly, Heated)
• PKA: 12.87±0.70(Predicted)
• CAS DataBase Reference: 7-epi-Clindamycin(CAS DataBase Reference)
• NIST Chemistry Reference: 7-epi-Clindamycin(16684-06-3)
• EPA Substance Registry System: 7-epi-Clindamycin(16684-06-3)

Safety Data

• Hazardous Substances Data: 16684-06-3(Hazardous Substances Data)

Usage

Description

7-epi-Clindamycin, also known as Clindamycin EP Impurity C, is an epimer of Clindamycin (C580000), a semi-synthetic antibiotic derived from Lincomycin, an antibacterial agent. It plays a significant role in the pharmaceutical industry, particularly in the synthesis of other compounds and as an impurity in bulk drugs.

Uses

Used in Pharmaceutical Industry:
7-epi-Clindamycin is used as an impurity in the bulk drug Clindamycin (C580000) for the development and manufacturing of semi-synthetic antibiotics. Its presence is crucial for the production process and quality control of the final antibiotic product.
Used in Synthesis of Compounds:
7-epi-Clindamycin serves as an intermediate in the synthesis of 7-Epiclindamycin 2-Phosphate (>90%) (E582505), which is another impurity of Clindamycin. This synthesis is essential for the pharmaceutical industry to ensure the purity and efficacy of the final antibiotic product.

Upstream product

• 859-18-7 lincomycin hydrochloride 

Downstream Products

• 147650-54-2 C₂₁H₃₇ClN₂O₅S 
• 21462-39-5 clindamycin hydrochloride 

Relevant articles and documents

Preparation method for clindamycin hydrochloride

The invention specifically relates to a preparation method for clindamycin hydrochloride, belonging to the field of pharmaceutical chemistry. The preparation method comprises the following steps: (1) subjecting lincomycin hydrochloride and a Vilsmeier reagent to a chlorination reaction to obtain a chlorinated solution, wherein heating is gradually carried out in the process of the reaction; (2) cooling the chlorinated solution to 2 to 6 DEG C at a cooling rate of 14 to 20 DEG C/h, then carrying out a hydrolysis reaction in an aqueous solution of sodium hydroxide and then successively carrying out extraction, washing and concentration so as to obtain clindamycin free alkali; (3) subjecting the clindamycin free alkali and a saturated ethanol solution of hydrogen chloride to a salt formation reaction and carrying out crystallization, cooling, low-temperature crystallization and centrifugal washing so as to obtain a clindamycin hydrochloride alcohol adduct; and (4) subjecting the clindamycin hydrochloride alcohol adduct to dealcoholysis, crystallization, pumping filtration and drying so as to obtain clindamycin hydrochloride. Through optimization of the preparation method, yield is increased; impurity content is substantially reduced; and high-purity clindamycin hydrochloride is obtained.

Composition and method for rectal delivery of a lincosamide antibiotic drug

A suppository composition and method for rectal administration of a lincosamide antibacterial drug, such as clindamycin, lincomycin, or pirlimycin, is disclosed. The composition is a rectal suppository containing an antimicrobially effective amount of the lincosamide in particulate form dispersed in a Hard Fat suppository base, preferably a Hard Fat NF suppository base. The most preferred suppository compositions of the present invention have long term storage stability, while maintaining effectiveness against bacterial infections.